Patents by Inventor David D. Hile

David D. Hile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190142971
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 16, 2019
    Inventors: Stephen G. Hoge, Örn Almarsson, David D. Hile, Ciáran Lawlor, John Podobinski, Staci Sabnis, Antonin De Fougerolles, Divakar Ramakrishnan, Kristy M. Wood
  • Patent number: 10258698
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 16, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, Örn Almarsson, David D. Hile, Ciarán Lawlor, John Podobinski, Staci Sabnis, Antonin de Fougerolles, Divakar Ramakrishnan, Kristy M. Wood
  • Publication number: 20160038612
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Inventors: Stephen G. Hoge, Öm Almarsson, David D. Hile, Ciarán Lawlor, John Podobinski, Staci Sabnis, Antonin de Fougerolles, Divakar Ramakrishnan, Kristy M. Wood
  • Publication number: 20140336114
    Abstract: The present invention provides formulations of cysteine knot proteins, including TGF-? superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-? superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation.
    Type: Application
    Filed: November 25, 2013
    Publication date: November 13, 2014
    Applicant: STRYKER CORPORATION
    Inventors: David D. Hile, Gregg Strohmeier
  • Publication number: 20040013688
    Abstract: A bioadhesive mucosal delivery system is used in concert with systemic immunization to develop long-lasting immune responses correlative to protective immunity, especially for the prevention of infection with malaria, tularemia, anthrax, and H. pylori. First, the method provides controlled delivery of protective antigens, such as ODNs, to a mucosal site resulting in “priming” of mucosal receptors. Second, the method augments this mucosal prime with parenteral stimulation. In another embodiment, an intranasal vaccine is used in the treatment of tularemia and other bacterial and viral inhalation antigens. The use of CpG motifs in bacterial DNA allows for the activation of the innate immune response that is characterized by the production of immunostimulatory cytokines and polyreactive antibodies. The rapid response system limits the spread of the pathogen prior to specific immunity activation.
    Type: Application
    Filed: July 3, 2003
    Publication date: January 22, 2004
    Applicant: Cambridge Scientific, Inc.
    Inventors: Donald L. Wise, Debra J. Trantolo, David D. Hile, Stephen A. Doherty